(Q37964565)

26 August 2017

Targeted therapies in metastatic renal cell carcinoma: overview of the past year (English)

1 reference

metastatic renal cell carcinoma

26 August 2017

1 reference

1 reference

Marine Gross-Goupil

1

1 reference

26 August 2017

Christophe Massard

series ordinal

2

1 reference

26 August 2017

Alain Ravaud

series ordinal

3

1 reference

26 August 2017

1 February 2012

1 reference

26 August 2017

Current urology reports

1 reference

26 August 2017

13

1 reference

26 August 2017

1

1 reference

26 August 2017

16-23

1 reference

https://scigraph.springernature.com/pub.10.1007/s11934-011-0232-y

26 August 2017

0 references

cites work

Clinical practice guidelines for the treatment of metastatic renal cell carcinoma: today and tomorrow.

1 reference

https://api.crossref.org/works/10.1007%2FS11934-011-0232-Y

New perspectives on the treatment of metastatic renal cell carcinoma: an introduction and historical overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-011-0232-Y

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-011-0232-Y

Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-011-0232-Y

Kinase targets in renal-cell carcinomas: reassessing the old and discovering the new.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-011-0232-Y

Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-011-0232-Y

Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-011-0232-Y

A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-011-0232-Y

Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-011-0232-Y

Novel potent orally active multitargeted receptor tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of 2-indolinone derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-011-0232-Y

A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-011-0232-Y

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-011-0232-Y

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-011-0232-Y

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-011-0232-Y

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-011-0232-Y

ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-011-0232-Y

The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-011-0232-Y

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-011-0232-Y

Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-011-0232-Y

The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-011-0232-Y

Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-011-0232-Y

Benefit of cytoreductive nephrectomy in metastatic RCC: do we learn from retrospective studies and small prospective studies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-011-0232-Y

Multi-modal treatment for metastatic renal cancer: the role of surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-011-0232-Y

Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-011-0232-Y

Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-011-0232-Y

Biomarkers of response and resistance to antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-011-0232-Y

Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-011-0232-Y

Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-011-0232-Y

Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-011-0232-Y

Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-011-0232-Y

Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-011-0232-Y

Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-011-0232-Y

Hypothyroidism in patients with renal cell carcinoma: blessing or curse?

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22139625

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11934-011-0232-Y

1 reference

release_ngp3mwyaffb6bi35rmkrswicim

26 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ngp3mwyaffb6bi35rmkrswicim

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference